검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Asparaginase Erwinia chrysanthemi (Asparaginase Erwinia chrysanthemi) medac GmbH·Acute Myeloid Leukemia 42 trials |
|---|---|
Overview Program | Asparaginase Erwinia chrysanthemi |
Overview Company | medac GmbH |
Overview Modality | ADC |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; T Acute Lymphoblastic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | (hydrolysis of circulating asparagine) and are associated with similar efficacy and toxicity patterns |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi .. For several decades, asparaginase has been considered world-wide as an essential component of combination chemotherapy for the treatment of childhood acute lymphoblastic leukemia (ALL). Discovered over 60 years ago, two main unmanipulated asparaginase products originated from primar… |
Clinical OS | 1.97 |
Clinical Result source | ClinicalTrials.gov NCT04326439 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Asparaginase Erwinia chrysanthemi (Asparaginase Erwinia chrysanthemi) medac GmbH·Acute Myeloid Leukemia 42 trials |
|---|---|
Overview Program | Asparaginase Erwinia chrysanthemi |
Overview Company | medac GmbH |
Overview Modality | ADC |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; T Acute Lymphoblastic Leukemia |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | (hydrolysis of circulating asparagine) and are associated with similar efficacy and toxicity patterns |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi .. For several decades, asparaginase has been considered world-wide as an essential component of combination chemotherapy for the treatment of childhood acute lymphoblastic leukemia (ALL). Discovered over 60 years ago, two main unmanipulated asparaginase products originated from primar… |
Clinical OS | 1.97 |
Clinical Result source | ClinicalTrials.gov NCT04326439 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교